
Opinion|Videos|November 21, 2023
Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation
For patients with BRAF-mutant metastatic melanoma, doctors assess symptoms and disease status to determine if they should start treatment with combination immunotherapy, or 8-12 weeks of BRAF/MEK targeted therapy before switching to immunotherapy, which offers the possibility of durable responses or cure.
Advertisement
Advertisement
Related to this article

Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
Botensilimab Plus Balstilimab Yields Durable OS in Recurrent Ovarian Cancer
3
FSHR-Directed CAR T-Cell Therapy Yields Instance of Stable Disease in Recurrent Ovarian Cancer
4
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management
5

